• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cohero raises $13.3m for connected inhaler tech

February 1, 2017 By Sarah Faulkner

Cohero HealthCohero raises $13.3m for connected inhaler tech said today that it raised more than $13.3 million, according to regulatory filings, in equity and Series A preferred stock. The company sold nearly all of its total offering amount of $13.6 million before closing the round. Over 50 investors have contributed to the offering, which had its 1st sale in October last year.

The company said it plans to use part of the funds for general working capital purposes, including the payment of salaries.

Cohero’s portfolio includes the BreatheSmart comprehensive respiratory disease management platform, which was designed to track medication use and measures lung function.

In December, H&T Presspart and Cohero launched a connected metered-dose inhaler designed to improve adherence and optimize care for patients with asthma and COPD. It is the 1st connected inhaler integrated with Cohero Health’s BreatheSmart platform.

The 2 companies developed the metered-dose inhaler over the course of a multi-year agreement. Improving patient adherence is vital, the companies said, as less than half of patients take their preventer medications as prescribed. This can result in poor symptom management, hospitalization and avoidable death.

Sensors within the inhaler can track real-time medication use and quality of medication delivery. The data is wirelessly shared to the BreatheSmart app, which can alert patients with medication reminders and provide monthly summary reports. Patients can choose to share the collected data with their families and healthcare providers, who can then access the information via a web app on a secure, HIPPA-compliant server. The technology can also be integrated with electronic medical records to transfer patient data.

The inhaler also features an FDA-approved  mechanical dose counter which allows pharmaceutical companies to easily transition current products to connected devices. H&T Presspart and Cohero Health are working with pharmaceutical manufacturers to leverage the technology for pipeline development, according to the companies.

Filed Under: Featured, Funding Roundup, Patient Monitoring, Respiratory Tagged With: Cohero Health

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS